Is Liminatus Pharma, Inc. (LIMN) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2023
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 175.7% / 30% | 4.8% / 30% | 10.3% / 30% | N/A | ✗ NOT HALAL |
| DJIM | 175.7% / 33% | 4.8% / 33% | 10.3% / 33% | N/A | ✗ NOT HALAL |
| MSCI | 715.9% / 33% | 19.4% / 33% | 42.1% / 33% | N/A | ✗ NOT HALAL |
| S&P | 175.7% / 33% | 4.8% / 33% | 10.3% / 33% | N/A | ✗ NOT HALAL |
| FTSE | 715.9% / 33% | 19.4% / 33% | 42.1% / 50% | N/A | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | 0.0% | |
| Operating Margin | 0.0% | |
| Net Margin | 0.0% | |
| Return on Assets (ROA) | -48.1% |
Cash Flow & Balance Sheet
| Operating Cash Flow | -$3M |
| Free Cash Flow | -$3M |
| Total Debt | $16M |
| Current Ratio | 0.4 |
| Total Assets | $2M |
Price & Trading
| Last Close | $0.20 |
| 50-Day MA | $0.51 |
| 200-Day MA | $2.93 |
| Avg Volume | 9.1M |
| Beta | 0.5 |
|
52-Week Range
$0.18
| |
About Liminatus Pharma, Inc. (LIMN)
Liminatus Pharma, Inc. operates as a pre-clinical stage biopharmaceutical company that develops novel cancer therapies. It is developing CD47, a high affinity humanized anti CD47 antibody that has the potential to translate into clinic for CD47 SIRPa blocking and restoring the anti-tumor function of innate immune cells without inducing hemagglutination or hemolysis. The company was founded in 2018 is based in LA Palma, California.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is Liminatus Pharma, Inc. (LIMN) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), Liminatus Pharma, Inc. is Not Halal. The company fails one or more screening criteria. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is Liminatus Pharma, Inc.'s debt ratio?
Liminatus Pharma, Inc.'s debt ratio is 175.7% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 715.9%.
What are Liminatus Pharma, Inc.'s key financial metrics?
Liminatus Pharma, Inc. has a market capitalization of $7M.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.